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Background
Exosomes are small endosome-derived vesicles ranging
from 30-120 nm in diameter secreted from cells through
exocytosis and, in cancer context, are able to prepare
metastasis niche and suppress host’s immune system.
Despite these pro-tumorigenic characteristics, exosomes
can be useful for several Biotechnological applications
such as biological anticancer vaccines, cancer diagnosis
and prognosis. Due to its property of carrying parental
cell’s protein and active nucleic acids there is an increasing
interest to use exosomes to track cancer metabolism
alterations in different conditions, for example, during
drug administration [1].
One of the most common types of cancer that develops
drug resistance during drug treatment is Melanoma. The
majority of drugs developed against melanoma targets
the oncogenic mutations in BRAF (BRAF V600E) that
are present in nearly 60% of cutaneous melanoma
tumors. Resistance to BRAFV600E inhibitors are classi-
fied in two main groups, Intrinsic Resistance and
Acquired Resistance, the second is developed after treat-
ment starts that happens mainly by MAPK reactivation
and RTK upregulation [2].
Various methods are being studied to overcome drug
resistance in melanoma, but there is a need to detect
when the resistant mechanism is arising to orientate
which approach to choose. This early detection has
demonstrated to be a difficult task especially during
advanced stages where there are several metastatic niches.
With this aim, our research project was designed to
create a method to follow tumor’s status through
melanoma-derived exosomes. As most types of melanoma
overexpress MART-1 we checked its expression, as well as
PDGFR-B and others proteins, in PLX4032 (V600E
mutated BRAF inhibitor) resistant and sensitive melanoma
cell lines to start to understand their potential to be exo-
somes-associated proteins in the development of acquired
resistance detection method[2].
Methodology
Cells were cultured in exosome depleted media by FBS
ultracentrifugation during 70 min at 100.000xg. Sensitive
(M229, M238, M249) and resistant (M229AR, M238AR,
M249AR) melanoma cell lines to PLX 4032 (vemurafenib)
were cultured until 75% of confluence and the supernatant
was processed to obtain the exosomes following 1500x g -
10 min, 17000x g - 15min and 160.000x g - 1 hour.
Results
To confirm this protocol it was done a Transmission Elec-
tron Microscopy (TEM), followed by Flow Cytometry
against CD63, an exosome molecular marker. TEM
showed an uniform size for exosomes ranging from 60- 90
nm in diameter and Anti-CD63 Flow Cytometry showed a
positive population of 99.1%. Western Blots were done
with the cells lines cited previously demonstrating that the
exosome’s protein content of MART-1, PDGFR-B, FGFR3
and others, corresponds to the parental cell.
Conclusion
Preliminary results show that exosomes can be useful tools
to predict cell’s metabolism. Here we present that protein
differential expression between sensitive and resistant
cell lines can be detected by exosome profile such as
PDGFR-B increased expression in resistant lines.
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